EX-99 2 ex991corporatepresentationro.htm Nemaura Roth Presentation







 

[ex991corporatepresentatio001.jpg]

 



Nemaura Medical Inc.

(NMRD)



ROTH Conference Presentation

March 11th 2015



1





 

[ex991corporatepresentatio002.jpg]

 


Presentation Overview

[ex991corporatepresentatio003.jpg]



2





 

[ex991corporatepresentatio004.jpg]

 


Our Background


Founded in January 2009 by Dr D F Chowdhury, the majority shareholder and the CEO


Biotech diagnostics research focused, headquarters in United Kingdom


Research facilities location at Science Park, Loughborough University, UK


Proprietary technology on transdermal (works through the skin) applications

diagnostic technologies

drug delivery technologies


Owned a family of related patents across various continents


Monitor commercialization process through sub-contracting to expert production and marketing vendors


Trading on NASDAQ OTC BB ticker: NMRD



3





 

[ex991corporatepresentatio005.jpg]

 


Key events


Date

Event

2009-14



2012



2014


2014


2015



2015

Cumulatively received over $2M in discretionary grants from UK government bodies


Successfully completed proof of concept studies in human

volunteers


Secured UK licensee for glucose monitoring – with $1.65m upfront Received trading symbol for OTC BB

Successfully completed clinical study in Type 1 and 2 diabetics


Awaiting approval for CE kite mark allowing sales of first product in Europe, HK and Saudi Arabia



4





 

[ex991corporatepresentatio006.jpg]

 


Our Core Business


Platform technology developed for Drug Delivery and Diagnostic Applications.


Current Focus: (Diagnostic Applications)


Non-invasive, continuous and painless monitoring of analyte / molecules. For example: glucose, lactate, prescription drugs.


Future Focus: (Drug Delivery)


Drug Delivery complementing diagnostic application.


For example, non invasive insulin delivery working in tandem with non invasive continuous glucose monitoring.



5





 

[ex991corporatepresentatio007.jpg]

 


Management Overview


Core Team of 21 People consisting of:


5 Board Members

4 Science Advisory Team Members

12 Technical Team Members


CEO: Dr D F Chowdhury: Microsystems and Nanotechnology from Cranfield University and PhD from the University of Oxford in nano-drug delivery; over 18 patents pending/granted.


CFO: K Farrar: MChem from University of Oxford, Chartered Accountant, 10 years with KPMG.


CTO: Prof. K. Khan: Launched over 60 products during his career in the Pharmaceutical Industry.


Medical Device & Regulatory Director: R Carson – A Pharmacologist with 20+ years experience in medical device design and registration in Europe and US.


6





 

[ex991corporatepresentatio008.jpg]

 


Government Support


Recipient of over $2m in several separate UK government grants awarded under independent competitive tendering process.


Grants awarded by UK Government Technology Strategy Board. Independent government assessor quoted:



‘The product could be a game changing technology’.



7





 

[ex991corporatepresentatio009.jpg]

 


Our Patents

Patents granted:

Region

Purpose

Expires

EU, China, Hong Kong

Patches patent for reverse iontophoresis:  Device patent describing construction of patches

Device patent for extracting glucose from skin non-

invasively.

June 2028

Europe, USA, Canada

Method patent for measuring relative level of two substances

Method patent to avoid finger prick to calibrate device

June 2021

Patents submitted:

Region

Purpose

Date applied/ Expiry

Australia, Brazil, Canada, India, Japan,

Patch patent for Reverse Iontophoresis

Device patent for construction of patches

Device patent for extracting glucose non-invasively.

June 2008/    June 2028

USA, Canada, Brazil, Europe, Japan, China, India, Australia, Qatar, United Arab Emirates

Method patent for cumulative measurement of analyte Algorithm patent for measurement of analyte without long delays

May 2012/ May 2032



8





 

[ex991corporatepresentatio010.jpg]

 


sugarBEAT™ Product


Our first commercialized product


sugarBEAT



[ex991corporatepresentatio011.jpg]



9





 

[ex991corporatepresentatio012.jpg]

 


sugarBEAT™ Product


sugarBEAT™ consists of three parts;


1.

a disposable patch (“Patch”)

2.

bluetooth enabled device (“Device”)

3.

smart phone app (“App”)



To use sugarBEAT™:


1.

Affix Patch to arm

2.

Connect Patch to adjacently worn Device via thin wire

3.

Device transmits real time data to App

4.

App can send data online to remote health care team



sugarBEAT™ provides up to 4 readings an hour for 12 hours or more.



10





 

[ex991corporatepresentatio013.jpg]

 



sugarBEAT™ Product – How it Works

[ex991corporatepresentatio014.jpg]



11





 

[ex991corporatepresentatio015.jpg]

 


sugarBEAT™ Product - Clinical Need

Diabetics suffer from unstable blood glucose levels


Diabetics therefore need to constantly monitor glucose levels.


Currently the most common monitoring method involves:

Extracting a drop of blood (droplet) by piercing the skin (finger pricking) several times a day.

This droplet is placed onto a test strip to provide a glucose reading.


Other methods require intrusive insertion into subcutaneous tissue.


The test strip market alone is currently generating over $10 Billion sales per annum.


There is huge demand for our non – intrusive and continuous monitoring method, which is convenient, timely and painless.


Our method will also provide substantial savings to diabetic patients.



12





 

[ex991corporatepresentatio016.jpg]

 

sugarBEAT™ Product – Image of Device

[ex991corporatepresentatio017.jpg]




13





 

[ex991corporatepresentatio018.jpg]

 


sugarBEAT™ Product – Illustration of AP

[ex991corporatepresentatio019.jpg]




14





 

[ex991corporatepresentatio020.jpg]

 


Our Technology - sugarBEAT™


Technical basis:


Works by passing a mild current across the skin that is barely perceptible, or non-perceptible.


This current pulls the glucose out of interstitial fluid, which is found just below the top layer of skin, into a reservoir in the patch.


The patch contains a sensor, which measures the amount of glucose analyzed.


An algorithm within the device converts this reading to a glucose concentration value.


This reading is displayed on the device with sound and / or buzzer alert



15





 

[ex991corporatepresentatio021.jpg]

 


Our Clinical Trials for sugarBEAT™


Clinical Data in Type I and II Diabetics:


Interim data accuracy in Clark Error Zones A+B >85%


20 subjects/60 patient day studies tested in 1,179 paired data points*


Note: Interim data presented in adjacent chart. Data validation currently in progress.



*Hemocue vs CGM

[ex991corporatepresentatio022.jpg]




16





 

[ex991corporatepresentatio023.jpg]

 


Regulatory Approval for sugarBEAT™


CE mark applied for which will permit sales in:


European Union countries


Saudi Arabia


Honk Kong


US and Japan Regulatory Approval to be sought 2016 onwards



17





 

[ex991corporatepresentatio024.jpg]

 

Target Market Analysis for sugarBEAT™ Product

[ex991corporatepresentatio025.jpg]




18





 

[ex991corporatepresentatio026.jpg]

 


Why sugarBEAT™ better than competition?


Competitors using invasive continuous technology have the following cons:


Cost – much more expensive


User market – mostly only suitable for type 1 diabetics which are only 10% of total diabetic market


Comfort – all require the continuous insertion of a measuring device into the body tissue which has high degree of user discomfort



19





 

[ex991corporatepresentatio027.jpg]

 


Why sugarBEAT™ better than competition?


Competitors using finger prick technology suffer following cons:


Finger prick is painful


Finger prick is not continuous – most users only finger prick 1-2 times a day even though WHO recommends 5-7 times a day




20





 

[ex991corporatepresentatio028.jpg]

 


Commercialization Process for sugarBEAT™



Manufacturing Development of Devices – Q2-Q4 2015



Manufacturing Development of Patches – Q2-Q4 2015



Mobile App development and launch – Q4 2015



Product Launch in HK, Saudi Arabia – Q4 2015



Product Launch in UK – Q1 2016



21





 

[ex991corporatepresentatio029.jpg]

 


Production and Operations for sugarBEAT™


We are dedicated R&D company.


All manufacture and sales therefore subcontracted to expert partners.


Preferred partners selected for:


Device manufacture


Sensor Manufacture


Patch Manufacture


Electronics



22





 

[ex991corporatepresentatio030.jpg]

 


Sales & Distribution for sugarBEAT™


Criteria for selecting specialist partners: (partner already selected for UK)



[ex991corporatepresentatio031.jpg]



23





 

[ex991corporatepresentatio032.jpg]

 


Financial Forcasts for sugarBEAT™


In Million ($ US Dollar)/ Year to March 31,

2016

2017

2018

2019

2020

Revenue

10

85

270

461

694

Cost of sales

7

42

136

244

366

Gross profits

3

43

134

217

328

Total expenses

10

15

14

24

29

Income before taxation

(7)

28

120

193

299

Taxation

- -

6

24

38

59

Net income

(7)

22

96

155

240




24





 

[ex991corporatepresentatio033.jpg]

 


Our Future Potential – Drug Delivery


Works by inverting technology so drugs delivered non-invasively into skin via a reservoir in the patch.


Technology suitable for:


Programmed drug delivery


On-demand drug delivery


Chrono-therapeutic drug delivery


Closed loop diagnostic and drug delivery


Basal Insulin expected to be first product chosen




25





 

[ex991corporatepresentatio034.jpg]

 


Contacts


Dr D F Chowdhury

Nemaura Medical Inc.

Holywell Park

Ashby Road

Loughborough

Leics,

LE11 3AQ

UK


Tel: +44 1509 222 912


Email: faz.chowdhury@nemaura.co. uk


www.nemauramedical.com

Bashir Timol

Nemaura Medical Inc.

Holywell Park

Ashby Road

Loughborough

Leics,

LE11 3AQ

UK


Tel: +44 1509 222 912


Email: bashir.timol@nemaura.co.uk



26